AUTL expects Q1 2026 earnings of -$0.26 per share on $26.13M revenue, matching year-ago levels.
Autolus Therapeutics will report Q1 2026 financial results on May 14 before the market opens. Analysts anticipate a loss of $0.26 per share, unchanged from the same quarter last year, alongside revenue of $26.13M.
Over the past year, AUTL has consistently surpassed earnings per share estimates, though revenue performance has varied. The company’s consensus estimates reflect stable expectations for the quarter, with no significant year-over-year growth projected.
No immediate market reaction details were provided ahead of the release.